<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>N-of-1 on Stephanie Rebecca</title><link>https://stephanierebecca.com/categories/n-of-1/</link><description>Recent content in N-of-1 on Stephanie Rebecca</description><generator>Hugo</generator><language>en-gb</language><lastBuildDate>Sun, 24 May 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://stephanierebecca.com/categories/n-of-1/index.xml" rel="self" type="application/rss+xml"/><item><title>N-of-1: peptides</title><link>https://stephanierebecca.com/posts/n-of-1-peptides/</link><pubDate>Sun, 24 May 2026 00:00:00 +0000</pubDate><guid>https://stephanierebecca.com/posts/n-of-1-peptides/</guid><description>&lt;p&gt;An N-of-1 trial (or single-subject design) is a personalised clinical trial where a single patient acts as their own study population. Instead of testing a drug on a large group of people, an individual receives sequential, randomised treatments or placebos over time to determine the optimal care. N-of-1 trials are a core tool in precision medicine to evaluate customised and off-label therapies when a traditional large-scale clinical trial isn&amp;rsquo;t possible, especially in ultra-rare diseases or chronic conditions.&lt;/p&gt;</description></item></channel></rss>